102 results
Page 4 of 6
8-K
EX-99.2
jnos4ks90wxok0
18 Mar 21
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights
8:31am
8-K
uwj4ptc4g62xzvtn456c
5 Jan 21
Regulation FD Disclosure
8:30am
8-K
EX-99.1
r4t zrk9rhzl
5 Jan 21
Regulation FD Disclosure
8:30am
8-K
EX-99.1
fdn qksjyu
5 Nov 20
Aeglea BioTherapeutics Reports Third Quarter 2020 Financial Results and Corporate Highlights
8:30am
8-K
EX-1.1
zcmlymv6s7hzr 0ti
28 Apr 20
Entry into a Material Definitive Agreement
4:28pm
424B5
lppcjxi4 1utoav51y
28 Apr 20
Prospectus supplement for primary offering
4:10pm
8-K
EX-99.1
q18uvyyd3
27 Apr 20
Regulation FD Disclosure
4:18pm
424B5
ca0yqinepgiuc3znkyct
27 Apr 20
Prospectus supplement for primary offering
4:09pm
8-K
eifqg 982ahkg2
16 Apr 20
Entry into a Material Definitive Agreement
8:49am
8-K
EX-1.1
vxem4 cp21u8fm
16 Apr 20
Entry into a Material Definitive Agreement
8:49am
424B5
pghfccwj7o
16 Apr 20
Prospectus supplement for primary offering
8:44am
8-K
EX-99.2
m3s5r87 29
13 Jan 20
Company Expects to Initiate a Phase 1/2 Trial in the Second Quarter of 2020
7:01am
8-K
EX-99.1
jjcsr45retfupt
3 Dec 19
Regulation FD Disclosure
8:00am